Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Recruiting 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

CNS 1

Conditions

Glioma 1

Interventions

Magnetic Resonance Spectroscopy 22Temozolomide 17Specimen Handling 13X-Rays 9Biopsy 9Radiotherapy 8Radiation 8trametinib 6Phantoms, Imaging 6Nuclear Medicine Department, Hospital 6Bevacizumab 6larotrectinib 4erdafitinib 4dabrafenib 4ulixertinib 3palbociclib 3abemaciclib 3Surgical Procedures, Operative 3Nivolumab 3Cyclophosphamide 3vorasidenib 2tipifarnib 2tazemetostat 2selpercatinib 2olaparib 2mirdametinib 2lutetium Lu 177 dotatate 2ivosidenib 2fluorodopa F 18 2fludarabine 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Glioma × Tomography, Optical Coherence × 90 days × Clear all
NCT05859334 2026-06-02

Testing the Anti-cancer Drug Erdafitinib for Brain Cancers That Have Returned or Progressed Following Treatment

National Cancer Institute (NCI)

Phase 2 Recruiting
30 enrolled
CNS

Glioma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡